Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 6/20 | 0.41 |
| ▸ | PGR | P06401 | 6/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.36 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25317588 | 0.89 | ALK (0.42) | ALKPGRKCNA5 | |
| SCHEMBL30507496 | 0.88 | ALK (0.42) | ALKPGRTRPV4DRD2SLC6A4 | |
| SCHEMBL25317462 | 0.88 | ALK (0.42) | ALKPGRTRPV4DRD2SLC6A4 | |
| SCHEMBL30507369 | 0.88 | PGR (0.40) | ALKPGRTRPV4KCNA5 | |
| SCHEMBL25318419 | 0.88 | PGR (0.40) | ALKPGRTRPV4KCNA5 | |
| SCHEMBL25317063 | 0.86 | PGR (0.41) | ALKPGRTRPV4DRD2SLC6A4 | |
| SCHEMBL25317686 | 0.86 | ALK (0.40) | ALKPGRTRPV4DRD2SLC6A4 | |
| SCHEMBL25319347 | 0.86 | ALK (0.41) | ALKPGRKCNA5 | |
| SCHEMBL25317873 | 0.85 | PGR (0.40) | ALKPGRTRPV4DRD2SLC6A4 | |
| SCHEMBL25317489 | 0.85 | PGR (0.40) | ALKPGRTRPV4DRD2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | ALK 4587/4885PGR 2819/4885TRPV4 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.